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TAP- and tapasin-dependent HLA-E surface expression
correlates with the binding of an MHC class I leader peptide
Veronique M. Braud*, David S.J. Allan*, Douglas Wilson† and 
Andrew J. McMichael*
Background: The human major histocompatibility complex (MHC) class Ib
molecule HLA-E is transcribed in most tissues but little is known about its
localisation within the cell. We have recently shown that HLA-E binds signal-
sequence-derived peptides from human MHC class I molecules in vitro. 
Results: Using a newly characterised antibody recognising HLA-E, we show
that HLA-E is expressed at the cell surface. We demonstrate that HLA-E
surface expression is correlated with the presence of MHC class I molecules
which provide suitable leader sequence peptides capable of binding to HLA-E.
Further studies on the interaction of HLA-E with molecules in the endoplasmic
reticulum revealed that HLA-E associates with the transporter associated with
antigen processing (TAP) and calreticulin, and that HLA-E expression is 
TAP-dependent and tapasin-dependent. In addition, HLA-E dissociates from
TAP upon binding of MHC class I leader sequence peptides.
Conclusion: These experiments establish that surface expression of HLA-E is
regulated by the binding of a restricted pool of peptides from the leader
sequence of MHC class I molecules. The correlation between HLA-E and MHC
class I surface expression might be relevant to the function of HLA-E. Our
results also show that, although these HLA-E binding peptides are derived from
signal sequences, they may be released back into the cytosol and subsequently
translocated by the TAP complex and loaded onto HLA-E molecules.
Background
Major histocompatibility complex (MHC) class Ia mol-
ecules present peptides derived from cytosolic proteins to
CD8+ T cells. Assembly of MHC class I molecules occurs
in the endoplasmic reticulum (ER) and requires peptide
translocation through the transporter associated with
antigen processing, TAP (reviewed in [1]). In human cells,
newly synthesised MHC class I heavy chains associate
with calnexin which is later displaced by the association of
β2-microglobulin (β2m) [2–4]. Following dissociation of
calnexin, class I–β2m heterodimers are stably associated
with another ER-resident protein, calreticulin [5]. Another
molecule, tapasin, which is associated with TAP and with
MHC class I–calreticulin complexes, acts as a bridge
between them. MHC class I association with TAP facili-
tates peptide binding and the class I molecules are
released and exported to the cell surface upon stable
loading of peptide [2,6–8].
Recently, some of the nonclassical MHC class Ib mol-
ecules have been shown to bind peptides to fulfil spe-
cialised antigen-presentation functions. HLA-G is mainly
expressed on human trophoblast and binds a wide range of
peptides in a TAP-dependent manner [9,10]. The non-
MHC-encoded CD1 may present peptides as well as
lipids and glycolipids to T cells [11–14]. The mouse Qa-2
molecule also has the capacity to present a diversity of nat-
urally processed peptides [15]. Murine H-2M3 presents
N-formylated peptides to specific T cells, and the presen-
tation requires TAP [16,17]. The mouse Qa-1 molecule
binds a very limited pool of peptides derived from MHC
class I leader sequences [18,19]. These observations
suggest that nonclassical MHC class Ib molecules bind
peptides in a similar way to classical MHC class I mol-
ecules and that, for most, loading is TAP-dependent. 
Some epitopes follow an alternative route to be presented
at the cell surface. Signal-sequence-derived peptides are
loaded onto HLA-A*0201 and exported to the plasma
membrane in the TAP negative cell line T2 [20,21]. This
suggests that some leader sequences might be degraded
within the ER and the resultant peptides loaded onto
newly synthesised class I molecules, independently of
TAP. However, presentation of certain epitopes located in
signal sequences requires TAP [22,23], and the nonclassi-
cal Qa-1 molecule presents leader sequence peptides in a
TAP-dependent manner [18]. 
Recently, we have shown that another human MHC class Ib
molecule, HLA-E, is able to bind signal-sequence-derived
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peptides similar to those binding to Qa-1 [18,19,24,25].
The optimum binding peptide is a nonamer, and using
alanine and glycine substitutions we established primary
anchor residues at positions 2 and 9 and secondary anchor
residues at position 7 and possibly 3. Until now, data sug-
gested that HLA-E was largely localised in the ER.
Neither mouse cells transfected with HLA-E and human
β2m, nor the LCL721.221 cell line (.221 cells), which only
expresses HLA-E and HLA-F, show cell-surface expres-
sion of HLA-E [25–27].
We report here that HLA-E is expressed at a low level on
the surface of cells. Its expression is correlated with co-
expression of human MHC class I molecules, providing
leader sequence peptides capable of binding to HLA-E.
Loading of these signal-sequence-derived peptides is
TAP and tapasin-dependent and HLA-E assembly
appears to be similar to classical MHC class I assembly.
Results
Maturation of HLA-E in lymphoblastoid cells detected by
the monoclonal antibody DT9
We recently characterised a mouse monoclonal antibody
DT9 that recognises cottontop tamarin MHC class I mol-
ecules and cross-reacts with human HLA-E and HLA-C
molecules. This antibody detects both HLA-E heavy
chains complexed with human β2m and free HLA-E
heavy chains, as shown by immunoprecipitations from B-
cell lines and the β2m-negative cell line Daudi respec-
tively (Figure 1). DT9 recognises the two previously
reported HLA-E alleles, which differ by a single amino-
acid residue at position 107, HLA-E-arginine-107 and
HLA-E-glycine-107 (Figure 1) [28]. Immunoprecipita-
tions from B-cell lines expressing different HLA haplo-
types demonstrated that DT9 does not cross-react with
HLA-A and HLA-B alleles but does recognise HLA-C
molecules (Figures 1,2a,2b and data not shown). The
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Figure 1
(a,b) Characterisation of DT9 reactivity by
immunoprecipitations and analysis by one-
dimensional isoelectric focusing
electrophoresis (1D-IEF). [35S]-methionine
and [35S]-cysteine-labelled cell lines: .45 (lane
1), .174 (lane 2), Daudi (lane 3), C1R (lane 4),
KM BCL (lane 5), .221 (lane 6), NR BCL (lane
7), JO BCL (lane 8), BM36.1 (lane 9), and
mouse L cells transfected with HLA-A*0301
and human β2m (lane 10) were used for
immunoprecipitations with DT9. An
immunoprecipitation in .221 cells using the
irrelevant antibody K918 is shown in lane 11.
Bands were identified according to the HLA
typing and compared with
immunoprecipitations with the anti-MHC class
I antibody W6/32 (data not shown). In (b),
nonspecific bands (NS) were seen in samples
processed in a similar way, but without
addition of any antibodies (data not shown). In
(a), the closed arrow indicates the 
HLA-E*0101 allele which has an arginine at
residue 107, and the open arrow the 
HLA-E*0103 and E-N3 alleles which have a
glycine at position 107. HLA typing was as
follows: .45 (HLA-A*0201, B*5101,
Cw*0102, E*0101); .174 (HLA-A*0201,
B*5101, Cw*0102, E*0101); Daudi (HLA-
A*0102, A*6601, B*5801, B*5802,
Cw*0302, Cw*0602, E*0103, E-N3); C1R
(HLA-B*3501, Cw*0401, E*0101); KM BCL
(HLA-A*0101, A*68, B*8, Cw*701, E*0101,
E*0101); .221 (HLA-E*0101); NR BCL 
(HLA-A*0101, A*0301, B*8, B*60, Cw*3,
Cw*0701, E*0101, E*0103); JO BCL 
(HLA-A*0201, A*0301, B*5101, B*5701,
Cw*1602, Cw*0602, E*0103, E-N3);
BM36.1 (HLA-A*0101, B*3501, Cw*4,
E*0101, E*0101).
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cross-reaction with HLA-C was confirmed in .221 cells
transfected with HLA-C alleles, in which staining with
DT9 was equivalent to that with the anti-MHC class I
antibody W6/32 (data not shown). 
We used DT9 to study the maturation of HLA-E in B-cell
lines by pulse-chase experiments followed by one-dimen-
sional isoelectric focusing electrophoresis (1D-IEF). In
homozygous B cell lines, both HLA-E alleles matured to
sialated forms after a 1 hour chase, indicating that the mole-
cule had left the ER and reached the Golgi network (Figure
2a,b). The more acidic bands appearing with time were
removed by treatment of the precipitate with neu-
raminidase, confirming that they represented the sialated
forms of HLA-E (see Supplementary material). The rate of
intracellular trafficking was slow compared with most HLA-
A and HLA-B molecules, which are sialated after
15–30 minutes [29,30]. HLA-E matured with a half-time
between 60 and 90 minutes. Mature HLA-E molecules dis-
appeared after 3–5 hours, implying that HLA-E turnover is
more rapid than that of classical class I molecules. 
Surface expression of HLA-E correlates with the binding of
MHC class I signal-sequence-derived peptides
DT9 was used to detect HLA-E at the cell surface by flow
cytometry. As shown in Figure 3, DT9 mAb did not stain
HLA-A, HLA-B, HLA-C and HLA-G negative .221 cells,
indicating that in these cells HLA-E does not traffic to the
plasma membrane. The weak staining by the anti-class I
antibody W6/32 was possibly due to surface expression of
HLA-F; a sialated form of HLA-F appeared after
90 minutes in a pulse-chase experiment using .221 cells
and W6/32 (data not shown). Lack of surface expression of
HLA-E in .221 cells was consistent with pulse-chase
experiments, which showed a single band representing
the nonsialated form of HLA-E retained in the ER
(Figure 4a). 
We previously reported that HLA-E, like the mouse Qa-1
molecule [18,19,24], binds in vitro peptides derived from
the leader sequence of some MHC class I molecules [25].
Because their leader sequences are shortened, peptides
capable of binding to HLA-E cannot be generated from
the endogenous HLA-E and HLA-F in .221 cells [25]. To
test whether lack of HLA-E surface expression in .221
cells could be explained by lack of binding of a signal-
sequence-derived peptide, we analysed the maturation
and expression of HLA-E in .221 cells transfected with
HLA-A*0201, whose leader sequence peptide binds to
HLA-E [25]. The .221-A*0201 cells, in contrast to .221,
were stained by DT9, suggesting that the leader peptide
might contribute to HLA-E surface expression (Figure 3).
The surface expression was low in comparison with the
expression of classical MHC class I molecules. Sialated
forms of HLA-E were also detected after 1 hour in a
pulse-chase experiment using DT9 in .221-A*0201 cells
(Figure 4b). It was confirmed that DT9 can detect HLA-E
binding to such leader sequence peptides as staining was
observed on .221 cells incubated at 26°C in the presence
of the leader-sequence peptide 3–11 from HLA-B*0801
but not with an irrelevant peptide (Figure 3). 
To rule out the possibility that HLA-E was binding an
HLA-A*0201 peptide distinct from the signal sequence-
derived peptide 3–11, we stained several other .221 cells
transfected with HLA-A and HLA-B alleles (Figure 3,
Table 1). The leader peptide 3–11 from these alleles dis-
plays some polymorphism, mainly at positions 2, 7 and 8 in
the peptide (Table 1). The corresponding leader peptides
were synthesised and tested for binding to HLA-E in the
in vitro peptide-binding assay previously described ([25];
data not shown). The substitution of the methionine for a
threonine at position 2 in the peptide, which is an anchor
residue, disrupted peptide binding whereas the
polymorphisms at positions 7 and 8 (leucine for valine or
phenylalanine) did not. DT9 bound to .221 cells trans-
fected with an HLA allele with a leader peptide capable of
binding to HLA-E (Figure 3, Table 1). The only excep-
tions were HLA-B*1302 and HLA-B*2705, which
induced a low level of HLA-E surface expression despite
having the inappropriate sequence (Table 1); this is being
fully investigated. Among the HLA alleles possessing a
leader peptide capable of binding to HLA-E, there was no
common amino-acid sequence with an HLA-E-binding
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Figure 2
HLA-E matures in lymphoblastoid cells. Pulse-chase experiments using
DT9 were performed in (a) KM BCL cells and (b) JO BCL cells. Cells
were pulsed for 15 min with [35S]-methionine and [35S]-cysteine and
chased for the times indicated (in min) along the top of the gels. DT9
immunoprecipitates were analysed by 1D-IEF. The numbers to the right
of the gels correspond to the number of sialic acid groups on HLA-E.
(a) 0 15 30 60 90 120 180 300
β2m
HLA-E
0
2
Cw701
(b) 0 15 30 60 90 120 180 300
β2m
HLA-E
0
2
Cw602
Cw1602
Current Biology
motif except for the leader sequence peptide 3–11. The
correlation therefore demonstrates that HLA-E expression
is significantly increased on binding of peptides derived
from the leader sequences of some MHC class I molecules
and implies that HLA-E binds a restricted pool of pep-
tides. The mouse HLA-E homologue Qa-1 also predomi-
nantly binds a single leader sequence peptide from mouse
MHC class I molecules [19,24].
HLA-E interaction with ER-resident molecules 
We studied HLA-E interactions with ER chaperone mol-
ecules and the TAP complex. Immunoprecipitations in
mild detergents such as digitonin maintain TAP–class I or
calreticulin-class I interactions [2,5]. The results of
immunoprecipitations in digitonin with anti-TAP2, and
anti-calreticulin antibodies are shown in Figure 5.
Whereas no HLA-E–β2m complexes were recovered in
the TAP-negative cell line T2 following an anti-TAP2
immunoprecipitation, HLA-E was associated with the
TAP complex in C1R-A2 and .221 cells (Figure 5a).
HLA-Cw*0401 and HLA-A*0201 were also associated
with TAP in C1R-A2 cells (Figure 5a and data not
shown). Thus, the HLA-E–TAP interaction occurred in
cells in which MHC leader sequence peptides capable of
binding to HLA-E were (C1R-A2) or were not (.221)
available. HLA-E does not mature rapidly (Figure 2a,b)
and might therefore stay associated with TAP while
waiting to be loaded with peptide. Ortmann et al. [2] pre-
viously failed to detect any MHC class I molecules associ-
ated with TAP in digitonin lysates of .221 cells. This
difference might be due to an insufficient exposure time,
as the amount of HLA-E is lower than classical class I
molecules. HLA-E–TAP association was also recently
observed in the trophoblast-derived choriocarcinoma cell
line JAR [31]. Immunoprecipitations in digitonin with an
anti-calreticulin antibody also showed that HLA-E associ-
ated with calreticulin in both TAP-negative and TAP-
positive cells (Figure 5b). HLA-E therefore seems to
behave like classical MHC class I molecules, associating
with both TAP and calreticulin. 
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Figure 3
HLA-E is expressed at the cell surface when
an MHC class I leader-sequence peptide
capable of binding to HLA-E is available. 
HLA-E cell surface expression was analysed
by flow cytometry on .221, .221-A*0201 and
.221-B*5801 cells using DT9, W6/32 or
BB7.2 monoclonal antibodies (mAb), and
K918 as an irrelevant antibody. HLA-E was
also stabilised at the cell surface by culturing
.221 cells at 26°C in the presence of
exogenous added peptides: MVDGTLLLL
from HLA-E leader sequence which is not
capable of binding to HLA-E in vitro and
VMAPRTVLL from HLA-B*0801 which can
bind to HLA-E.
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To confirm the above result and verify that in B-cell lines
HLA-E was part of the TAP–tapasin–class I–calreticulin
complexes described by Sadasivan et al. [5], we performed
two sequential immunoprecipitations in cells of the KM
B-cell line, .221-A*0201 and .221 cells. The first immuno-
precipitation was done in digitonin using an anti-TAP2
antibody in order to immunoprecipitate the multicomplex.
As the TAP and calreticulin association with MHC class I
is not maintained in NP-40 lysis buffer, we destabilised
the complex by addition of this detergent and performed a
second immunoprecipitation using DT9. HLA-E was
recovered from KM BCL, .221-A*0201 or .221, following
these sequential immunoprecipitations (Figure 5c). It has
previously been shown that an equal amount of class I can
be recovered after immunoprecipitation with an anti-TAP
antibody followed by an anti-calreticulin or an anti-class I
antibody, suggesting that the pool of class I molecules
associated with TAP is simultaneously associated with cal-
reticulin [5]. In light of the results shown in Figure 5c, we
conclude that HLA-E is also part of this multicomplex. 
Interaction with tapasin was also studied using the tapasin-
defective cell line .220 transfected with HLA-A*0201
(.220-A*0201) [32,33]. Whereas HLA-A*0201 is detected
at the cell surface of .220-A*0201 [32], no HLA-E surface
expression was observed (Figure 6), despite its presence in
.220-A*0201 cells, detected by immunoprecipitations using
W6/32 and DT9 (data not shown). No HLA-E molecules
were recovered following TAP coprecipitation in .220-
A*0201 (data not shown), consistent with the HLA-B8, -A1
and -G phenotype in .220 described elsewhere [33]. We
conclude that HLA-E assembly and maturation requires
tapasin, acting as a bridge between TAP and HLA-E–cal-
reticulin complexes. HLA-E therefore interacts with TAP,
calreticulin and tapasin, like classical MHC class I mole-
cules, although it binds signal-sequence-derived peptides.
Binding of signal-sequence-derived peptides to HLA-E is
TAP-dependent
We assessed the contribution of the TAP complex to the
loading of peptides onto HLA-E. Using DT9, we stained
three TAP-deficient cell lines in which TAP1 and TAP2
are either missing (T2 [34] and .174 [35]) or not functional
because of a frameshift mutation in one of the subunits
(BM36.1 [36]). A negligible level of HLA-E expression
was observed on the surface of the cells (Figure 7a and
data not shown). Furthermore, the sialated forms of 
HLA-E were not detected in a pulse-chase experiment in
T2-A3 cells (data not shown). In contrast, when BM36.1
infected by a recombinant vaccinia virus encoding both
human TAP1 and TAP2 subunits was metabolically
labelled for 6 hours, sialated HLA-E appeared (Figure 7b).
Research Paper  HLA-E surface expression Braud et al. 5
Figure 4
HLA-E remains in the ER in .221 cells but export to the Golgi can be
restored by transfection of HLA-A*0201. Pulse-chase experiments
using DT9 for the times indicated (in min) in (a) .221 and 
(b) .221-A*0201 cells were performed and analysed by 1D-IEF. The
numbers to the right of the gel in (b) correspond to the number of sialic
acid groups on HLA-E.
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Table 1
HLA-E cell-surface expression
HLA class I Signal sequence- .221 FACS 
alleles derived peptide transfectants staining
(residues 3–11) with DT9
mAb
Possessing a leader VMAPRTLLL .221-A*0101 +
sequence peptide VMAPRTLVL .221-A*0201 +
(residues 3–11) VMAPRTLVL .221-A*0211 +
capable of binding to VMAPRTLLL .221-A*0301 +
to HLA-E* VMAPRTLVL .221-A*2403 +
VMAPRTLVL .221-A*2501 +
VMAPRTLLL .221-A*3601 +
VMAPRTVLL .221-A*0702 +
VMAPRTVLL .221-A*0801 +
VMAPRTLFL .221-G +
Not possessing a † .221 –
leader sequence VTAPRTLLL .221-B*1302 ±
peptide (residues VTAPRTVLL .221-B*1501 –
3–11) capable of VTAPRTLLL .221-B*2705 ±
binding to HLA-E* VTAPRTVLL .221-B*3505 –
VTAPRTVLL .221-B*4601 –
VTAPRTVLL .221-B*5101 –
VTAPRTLLL .221-B*5401 –
VTAPRTLLL .221-B*5501 –
VTAPRTVLL .221B*5801 –
*The binding of synthetic peptides was tested in an in vitro peptide-
binding assay, as previously described ([25] and data not shown). †.221
cells do not express HLA-A, HLA-B, HLA-C and HLA-G class I
molecules but express HLA-E and HLA-F, which have a shorter leader
sequence and lack the appropriate peptide capable of binding to HLA-E.
Together, these results demonstrate that HLA-E expres-
sion is TAP-dependent.
We then investigated whether HLA-E, like classical
MHC class I molecules, dissociates from TAP upon
binding of peptides translocated from the cytosol: .221
cells were metabolically labelled and permeabilised with
streptolysin O and after incubation with or without leader
peptides, TAP was precipitated in digitonin [2]. The rate
of dissociation of HLA-E from TAP was enhanced by the
introduction into the cytosol of the leader sequence
peptide from HLA-A*0201 which binds to HLA-E
(Figure 8, lane 2), compared to no peptide (lane 1) or the
HLA-E leader peptide (lane 3), which does not bind to
HLA-E [25]. Thus, leader-sequence peptides from MHC
class I molecules can be translocated by the TAP
complex, which is also important for loading onto HLA-E.
These results imply that, although located in leader
sequences, these peptides must reach the cytosol and then
be translocated back into the ER by the TAP complex to
be loaded onto HLA-E.
Discussion
We used an antibody that recognises HLA-E and HLA-C
molecules to demonstrate that HLA-E is stably expressed
at the surface of human cells that also express certain
MHC class I molecules. HLA-E surface expression corre-
lates with binding of signal sequence-derived peptides
from MHC class I molecules. HLA-E therefore binds a
restricted pool of peptides, in a similar fashion to the
mouse MHC class Ib Qa-1 molecule, which predomi-
nantly binds a single peptide derived from the signal
sequence of H-2D and H-2L class I molecules [18,19].
Mouse Qa-1 and HLA-E might have a similar and con-
served function; both have limited polymorphism, a broad
tissue distribution, a low cell-surface expression and a slow
maturation rate [37]. They also share some unique substi-
tutions in the binding groove, especially a serine replacing
a tryptophan at position 147, which disrupts the highly
conserved hydrogen bond to the main-chain carbonyl
oxygen of P8 of the peptide found in other MHC class I
molecules [25,38]. This might explain the restricted pool
of peptides, and the kinetics of HLA-E turnover observed
in pulse-chase experiments (Figure 2a,b). 
We also showed that HLA-E expression is TAP-depen-
dent and tapasin-dependent and that HLA-E associates
with calreticulin, tapasin and TAP. HLA-E assembly
therefore seems to be similar to MHC class I assembly.
This is consistent with HLA-E sharing many of the char-
acteristics of classical MHC class I molecules. First, the
percentage of amino-acid sequence homology between
HLA-E and HLA-A, HLA-B or HLA-C molecules varies
from 50 to 90%, depending on the exon [39]. Second,
6 Current Biology, Vol 8 No 1
Figure 5
HLA-E associates with TAP and calreticulin.
(a) TAP coprecipitation in digitonin lysate
using a rabbit anti-TAP2 serum was
performed in T2, C1R-A2 and .221 cells.
Immunoprecipitates were analysed by 1D-IEF.
(b) Calreticulin coprecipitation in digitonin
lysate using a rabbit anti-calreticulin serum
was also performed in T2, C1R-A2 and .221
cells and analysed by 1D-IEF. (c) Molecules
associated with TAP were first
immunoprecipitated in digitonin lysate using a
rabbit anti-TAP2 serum from .221-A*0201,
.221 and KM BCL cells. TAP-associated
molecules were then eluted in NP- 40 lysis
buffer and a second immunoprecipitation
using DT9 was performed. Samples were
analysed by 1D-IEF.
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Figure 6
HLA-E expression is tapasin-dependent. Flow cytometry staining of
.220-A*0201 cells using DT9 and BB7.2 monoclonal antibodies (mAb)
and K918 as an irrelevant antibody.
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HLA-E has a very similar structure to its classical MHC
counterparts (C. O’Callaghan et al., personal communica-
tion). Third, HLA-E heavy chain associates with β2m and
binds peptides [25,27,40]. Fourth, HLA-E tissue distribu-
tion matches classical MHC class I tissue distribution [41]. 
It is surprising that the loading of the signal-sequence-
derived peptide requires the presence of TAP, but similar
observations have been made for the mouse Qa-1 mole-
cule [18]. TAP-dependent HLA-E expression could result
from TAP acting as a chaperone in the ER. If leader
sequences are generated in the ER, HLA-E might load
peptides only when associated with TAP, without requir-
ing peptide translocation. This is, however, unlikely,
because HLA-E is not expressed at the cell surface of
BM36.1, which has a normal TAP1 subunit to interact
with class I, and a different cytosolic carboxy-terminal
domain in TAP2. Despite this nonfunctional TAP2, the
complex still assembles and can be immunoprecipitated
with an anti-TAP1 antibody [36]. It is therefore likely that
HLA-E associates normally with TAP in BM36.1, making
a simple non-transporting role for TAP quite unlikely.
The full-length leader sequences of MHC class I mol-
ecules, or a peptide generated from them, might recycle
back to the cytosol. Studies on the processing of signal
sequences suggest that some signal-sequence peptides are
released into the cytosol. The processing of the prepro-
lactin signal sequence in eukaryotic cells results in the
production of two fragments, the amino-terminal peptide
being released into the cytosol [42]. Peptides derived from
MHC class I signal sequences might follow this pathway,
particularly as the peptide binding to HLA-E is at the
amino terminus of the signal sequence. One other leader
sequence peptide known to be presented in a TAP-
dependent manner is also located at the amino terminus
[23]. In addition, other MHC class I leader sequence
peptides have been eluted from MHC class I or class II
molecules, all located at the amino terminus of the signal
sequence, close to the peptide binding to HLA-E [43,44].
This suggests that HLA class I signal sequences might all
be processed in a similar way. Further investigations are in
process to confirm these hypotheses. Another possibility is
that the full-length signal sequence from MHC class I
molecules, once released into the ER, cannot be degraded
by ER resident proteases (reviewed in [1]). Long peptides
or misfolded proteins can recycle back into the cytosol to
be further degraded by the proteasome to generate
nonamer peptides, which are then translocated back into
the ER through the TAP complex [45–48]. Signal
sequences from class I molecules could follow this route.
It is intriguing that the two nonclassical class I molecules
Qa-1 and HLA-E bind and present signal-sequence-
derived peptides at the surface of cells expressing MHC
class I molecules. It is interesting that HLA-E expression is
controlled not only by MHC class Ia molecules, but also by
HLA-G [41,49]. It is likely that HLA-E trafficks to the cell
surface of trophoblast cells because HLA-G leader peptide
3–11 can bind to HLA-E and HLA-E is expressed on .221-
G cells (Table 1) [25]. HLA-E might therefore have a func-
tion that correlates with the expression of other MHC class
I molecules. One possibility might be that HLA-E interacts
with a receptor on natural killer (NK) cells in order to
protect cells expressing MHC class I from NK cell-medi-
ated lysis. Alternatively, HLA-E might interact with CD8+
T cells, as the residues involved in CD8 interaction are
conserved in HLA-E [50]. HLA-E, like Qa-1, might there-
fore be involved in alloreactive responses and in immune
regulation by CD8+ T cells of CD4+ T cells expressing a
specific Vβ T-cell receptor [37,51,52]. The leader-sequence
peptides from MHC class I could also be displaced by spe-
cific peptides during bacterial or viral infections and HLA-
E might present these peptides to αβ or γδ T cells. 
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Figure 7
HLA-E expression is TAP-dependent. 
(a) FACS analysis of the TAP-negative cell
line BM36.1. Cells were stained with DT9 and
W6/32 monclonal antibodies (mAb), and
K918 as an irrelevant antibody. (b) CO BCL
cells (lane 1); BM36.1 untreated (lane 2),
infected with wild-type vaccinia virus (lane 3),
or infected with a vaccinia virus encoding the
two human subunits of TAP (lane 4) were
metabolically labelled for 6 h and
immunoprecipitations were carried out using
DT9 and analysed by 1D-IEF. The numbers to
the left of the gel in (b) correspond to the
number of sialic acid groups on HLA-E.
(a) (b)
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Conclusions
Here, we demonstrate for the first time that HLA-E is
stably expressed at the cell surface. HLA-E surface
expression correlates with the expression of those
MHC class I molecules which possess a peptide in their
leader sequence capable of binding to HLA-E. Like
classical MHC class I molecules, HLA-E is associated
with calreticulin, tapasin and TAP in the ER and HLA-E
surface expression is TAP-dependent and tapasin-
dependent. These findings might be relevant to protec-
tion from NK cell-mediated lysis.
Materials and methods
Cell lines and HLA class I typing
The mutant cell lines LCL721.221 (.221), .221-A*0201 and 
.220-A*0201 were kindly provided by R.DeMars (University of Wiscon-
sin, Madison). All the other .221 cells transfected with various HLA
alleles were generously given by P. Parham (Stanford University, Stan-
ford, California). Mouse L cells transfected with HLA-A*0301 and
human β2m were provided by F. Lemonnier (Pasteur Institute, Paris).
The HLA-A, -B, and -C typing was performed on DNA by PCR utilising
sequence-specific primers (PCR–SSP), as described elsewhere
[53,54]. The HLA-E DNA typing was kindly performed by R. Steffensen
(Aalborg Hospital, Aalborg, Denmark), by PCR utilising sequence-spe-
cific oligonucleotides (PCR–SSO), according to the 12th International
Histocompatibility Workshop protocol.
Antibodies, peptides and vaccinia viruses
DT9 was generated by immunisation of mice with purified tamarin MHC
class I molecules (using anti-class I antibody BB7.7), and screened by
flow cytometry on tamarin B-cell lines, tamarin T-cell lines and human
B-cell lines. W6/32 detects a conformational epitope on human MHC
class I molecules. BB7.2 sees a specific determinant on HLA-A2 and
A69 molecules loaded with peptides. K918 monoclonal antibody,
which recognises H-2Kd molecules was used in all the experiments as
an irrelevant antibody, and was kindly provided by A. Townsend (Insti-
tute of Molecular Medicine, Oxford). A polyclonal rabbit anti-TAP2
serum kindly provided by J. Neefjes (The Netherlands Cancer Institute,
Amsterdam) was used for the coprecipitations in digitonin lysates. The
polyclonal rabbit anti-calreticulin serum was purchased from Affinity
Bioreagents. Peptides from MHC class I leader sequences were syn-
thesised on a SMPS-350 automated peptide synthesiser (Zinsser Ana-
lytical) by conventional Fmoc chemistry, precipitated with ether,
lyophilised, and subjected to HPLC to ascertain purity (> 95%). The
vaccinia virus encoding human TAP1 and TAP2 subunits (hTAP1
+2-Vac) was kindly provided by J. Yewdell (National Institute of Allergy
and Infectious Diseases). BM36.1 cells were infected with 5 plaque
forming units (PFU) per cell, with wild-type vaccinia virus (WT-Vac) or
hTAP1+2-Vac for 90 min at 37°C during the metabolic labelling.
Flow cytometry
HLA-E and HLA class I expressions were monitored by flow cytometry
using the panel of antibodies described above and a fluorescein-conju-
gated goat anti-mouse IgG F(ab’)2. Cells were analysed on a FACScan
(Becton Dickinson). For the stabilisation of HLA-E at the cell surface, .221
cells were cultured overnight at 26°C in the presence of 50 µM peptides. 
Pulse-chase experiments
Pulse-chase experiments were performed as previously described [30].
Cells were pulse-labelled for 15 min with 100 µCi [35S]-methionine +
[35S]-cysteine (Amersham) and chased for the indicated times. A stan-
dard immunoprecipitation of HLA-E was performed using DT9.
Samples were analysed by 1D-IEF, followed by autoradiography. 
Coprecipitation in digitonin lysates
Metabolically labelled cells were lysed in digitonin lysis buffer, as previ-
ously described [7] A standard immunoprecipitation was then per-
formed by addition of the anti-TAP2 or anti-calreticulin polyclonal rabbit
sera (10 µl and 5 µl respectively). For the sequential immunoprecipita-
tions, after immunoprecipitation by the anti-TAP2 antibody in digitonin,
dried beads binding the multicomplex calreticulin–class I–tapasin–TAP
were resuspended in NP-40 lysis buffer. Supernatants containing the
molecules dissociated from TAP were subjected to a second immuno-
precipitation with DT9. 
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Figure 8
HLA-E dissociates from TAP on binding of MHC leader-sequence
peptide. Metabolically labelled .221 cells were permeabilized using
streptolysin O and incubated for 10 min at 37°C, with no peptide 
(lane 1), VMAPRTLVL peptide (lane 2), or MVDGTLLLL peptide 
(lane 3) to allow transport through the TAP transporter. The
VMAPRTLVL peptide from the leader sequence of HLA-A*0201, is
capable of binding to HLA-E in vitro, whereas the MVDGTLLLL
peptide from HLA-E leader sequence is not. Cells were then lysed in
digitonin. TAP and molecules associated with TAP were
immunoprecipitated using a rabbit anti-TAP2 serum. Precipitates were
analysed by 1D-IEF.
1 2 3
β2m
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Dissociation of MHC class I molecules from TAP
Metabolically labelled cells were washed in transport buffer (5 mM
Hepes pH 7.3, 130 mM KCl, 10 mM NaCl, 1 mM CaCl2, 2 mM EGTA,
2 mM MgCl2) and permeabilized by addition of 2.5 IU ml–1 streptolysin
O (Wellcome Diagnostic) for 4 min at 37°C. Peptides and ATP were
added at a final concentration of 100 µM and 10 mM respectively, and
cells were incubated for another 10 min at 37°C, to allow translocation
through the TAP complex. Transport was stopped by addition of
10 mM EDTA and 0.02% NaN3. A standard TAP coprecipitation in digi-
tonin was then performed as described above. 
Supplementary material
Figure S1 showing identification of the sialated forms of HLA-E and
Figure S2 demonstrating HLA-E cell-surface expression when an MHC
class I leader-sequence peptide capable of binding to HLA-E is avail-
able are published with this paper on the internet.
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